The Thierry Latran Foundation 10th Call for projects opened in December 2017
The Thierry Latran Foundation was established in 2008 to a) finance basic, applied and clinical research with potential therapeutic benefit in sporadic ALS (Amyotrophic Lateral Sclerosis) and b) to support academic and industrial scientific research efforts in Europe to cure this disease.
The Foundation has enabled to reach significant milestones in terms of understanding ALS disease mechanisms and developments. After having paved the way for such progress, the Foundation will, for this new Call, focus on on-going most promising therapeutic targets, to validate or invalidate them:
The Thierry Latran Foundation opened its 10th call for projects for a total amount up to € 400 000.
Scientific themes were
Applicants are encouraged to submit projects that bring results from previously TLF-funded research closer to therapeutic or diagnostic valorisation.
- Researcher with a position within an institution for the duration of the project
- Teams based in EU-member states or in a country belonging to the Horizon 2020 Third Country Agreements (Iceland, Norway, Albania, Bosnia and Herzegovina, the former Yugoslav Republic of Macedonia, Montenegro, Serbia, Turkey, Israel, Moldova, Switzerland, Faroe Islands, Ukraine)
- Applications involving a single or several European research teams
- Applications from public, private and for-profit institutions
- Compliance to Thierry Latran Foundation call for project policy
We received 67 abstracts coming from 12 different countries
Since inception, 777 projects were submitted to the Foundation.
Each Member of the Scientific Advisory Board (SAB), assessed independently the 82 abstracts taking into account their scientific quality and their relevance to the objectives of the Foundation. During the process, the members of the Scientific Committee with a conflict of interest did participate neither to assessment nor to discussion.
These assessments have been consolidated and anonymized. A meeting of the Scientific Committee was held in March 2017 for selection, validated by the Foundation. 9 projects were selected for full application.
Each of the 9 application was analyzed by 2 different ‘referees’, specialized on the theme of the project and having no connection with the applicants. The members of the Scientific Committee met in Oxford in June to assess the projects on the basis of the opinion of the “referees” and to classify them into 3 groups A (strong recommendation for funding) B (projects recommended to be financed according to the available budget) and C (projects not recommended for funding). The SAB’s recommendations were presented to the Executive Committee in June 2018.
At the end of the process three projects were selected, meeting the selection criteria i.e. scientific excellence and contribution to the development of a diagnostic tool or a therapy.
Project 1 : (3-7)T- ALS
Virginie CALLOT, Centre de Résonance Magnétique Biologique et Médicale (CRMBM-CEMEREM), CNRS, Aix-Marseille University, Hôpital de la Timone APHM, Marseille, France1. (3-7)T- ALS
Project 2: DRUG- C9DPR
Nicolas CHARLET – BERGUERAND, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Strasbourg, France2. DRUG- C9DPR
Project 3 : TRiALS
Francesco ROSELLI, Department of Neurology, Ulm University School of Medicine, Germany3. TRiALS
The Thierry Latran Foundation is extremely grateful to the Scientific Advisory Board who performed the selection
Pr Wim Robberecht (Leuven University, Belgium) (President)
Pr Caterina Bendotti (Mario Negri Institute, Milano, Italy)
Dr Séverine Boillée (ICM, Paris, France)
Dr Jan Egebjerg (Lundbeck, Denmark)
Pr Linda Greensmith (University College of London, UK)
Pr Eva Hedlund (Karolinska Institute, Stockholm, Sweden)
Pr Albert Ludolph (Ulm University, Germany)
Pr Leonard H Van den Berg (Utrecht University, The Netherlands)
and to Elke Bogaert , SAB secretary (PHD in Neurosciences, Leuven) who drove the process.